EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment

Yutaka Takahara iD, Ryudai Abe, Sumito Nagae, Takuya Tanaka, Yoko Ishige, Ikuyo Shionoya, Kouichi Yamamura, Kazuaki Nishiki, Masafumi Nojiri, Ryo Kato, Shohei Shinomiya, Taku Oikawa

Thoracic Cancer · 2023

DOI: 10.1111/1759-7714.15161 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, 2023. Verfasst von Yutaka Takahara und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Several options for second‐line therapy are available for patients with advanced non‐small cell lung cancer (NSCLC); however, the optimal therapy remains unclear. Docetaxel (DTX) monotherapy and DTX plus ramucirumab (RAM) are the recommended second‐line treatment options. However, the efficacy of these treatments remains unsatisfactory. The aim of this study was to identify the clinical characteristics of patients with NSCLC who respond to DTX or DTX + RAM and factors that predict response.

Methods

Patients with NSCLC treated with DTX or DTX + RAM after second‐line therapy were retrospectively analyzed. Patients were compared with those who responded or did not respond to the post‐treatment efficacy assessment.

Results

Of 53 patients, 12 (22.6%) had lung cancer that responded to DTX or DTX + RAM therapy (response group). Multivariate analysis identified the absence of immune checkpoint inhibitors (ICIs) in the immediate prior therapy and a reduced dose of DTX after the second cycle as significant independent risk factors predicting nonresponse to DTX and DTX + RAM therapy in patients with NSCLC. The overall survival was significantly longer in the response group compared to the nonresponse group ( p = 0.016).

Conclusions

Our results suggest that DTX and DTX + RAM therapies immediately after treatment with ICI‐containing regimens as well as continuation of DTX without dose reduction after the second cycle may increase the response rate and prolong survival in patients with NSCLC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansRamucirumabDocetaxelRetrospective StudiesAntibodies, Monoclonal, HumanizedAntibodies, MonoclonalAntineoplastic Combined Chemotherapy Protocols

Stichwörter der Autor:innen

NSCLCdocetaxelimmune checkpoint inhibitorramucirumabsecond-line therapy

Substanzen

RamucirumabDocetaxelAntibodies, Monoclonal, HumanizedAntibodies, Monoclonal

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Kanazawa Medical University, Ishikawa, Japan.

ORCID-Profile: Yutaka Takahara

Zitieren

APA

Takahara, Y., Abe, R., Nagae, S., Tanaka, T., Ishige, Y., Shionoya, I., Yamamura, K., Nishiki, K., Nojiri, M., Kato, R., Shinomiya, S., & Oikawa, T. (2023). Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment. Thoracic Cancer. https://doi.org/10.1111/1759-7714.15161

Vancouver

Takahara Y, Abe R, Nagae S, Tanaka T, Ishige Y, Shionoya I, et al. Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment. Thoracic Cancer. 2023. doi:10.1111/1759-7714.15161

BibTeX
@article{Takahara2023,
  author = {Takahara, Yutaka and Abe, Ryudai and Nagae, Sumito and Tanaka, Takuya and Ishige, Yoko and Shionoya, Ikuyo and Yamamura, Kouichi and Nishiki, Kazuaki and Nojiri, Masafumi and Kato, Ryo and Shinomiya, Shohei and Oikawa, Taku},
  title = {Investigation of response of patients with non‐small cell lung cancer to docetaxel (plus ramucirumab) therapy in second‐line treatment},
  journal = {Thoracic Cancer},
  year = {2023},
  doi = {10.1111/1759-7714.15161}
}
Kostenlos starten →